Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. / Leng, Donglei; Kissi, Eric Ofosu; Löbmann, Korbinian; Thanki, Kaushik; Fattal, Elias; Rades, Thomas; Foged, Camilla; Yang, Mingshi.

In: AAPS PharmSciTech, Vol. 20, No. 3, 137, 07.03.2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Leng, D, Kissi, EO, Löbmann, K, Thanki, K, Fattal, E, Rades, T, Foged, C & Yang, M 2019, 'Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy', AAPS PharmSciTech, vol. 20, no. 3, 137. https://doi.org/10.1208/s12249-019-1344-9

APA

Leng, D., Kissi, E. O., Löbmann, K., Thanki, K., Fattal, E., Rades, T., Foged, C., & Yang, M. (2019). Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. AAPS PharmSciTech, 20(3), [137]. https://doi.org/10.1208/s12249-019-1344-9

Vancouver

Leng D, Kissi EO, Löbmann K, Thanki K, Fattal E, Rades T et al. Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. AAPS PharmSciTech. 2019 Mar 7;20(3). 137. https://doi.org/10.1208/s12249-019-1344-9

Author

Leng, Donglei ; Kissi, Eric Ofosu ; Löbmann, Korbinian ; Thanki, Kaushik ; Fattal, Elias ; Rades, Thomas ; Foged, Camilla ; Yang, Mingshi. / Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. In: AAPS PharmSciTech. 2019 ; Vol. 20, No. 3.

Bibtex

@article{974f059271c749e98386714e15bc4254,
title = "Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy",
abstract = "Corticosteroid resistance poses a major challenge to effective treatment of chronic obstructive pulmonary diseases. However, corticosteroid resistance can be overcome by co-administration of theophylline. The aim of this study was to formulate the corticosteroid budesonide with theophylline into inhalable dry powders intended for pulmonary combination therapy. Four types of spray-dried powders were prepared: (i) budesonide and theophylline co-dissolved and processed using a 2-fluid nozzle spray drier, (ii) budesonide nanocrystals and dissolved theophylline co-dispersed and processed using a 2-fluid nozzle spray drier, (iii) dissolved budesonide and dissolved theophylline processed using a 3-fluid nozzle spray drier, and (iv) budesonide nanocrystals and dissolved theophylline processed using a 3-fluid nozzle spray drier. Spray drying from the solutions resulted in co-amorphous (i) and partially amorphous powders (iii), whereas spray drying of the nanosuspensions resulted in crystalline products (ii and iv). Even though budesonide was amorphous in (i) and (iii), it failed to exhibit any dissolution advantage over the unprocessed budesonide. In contrast, the dissolution of budesonide from its nanocrystalline formulations, i.e., (ii) and (iv), was significantly higher compared to a physical mixture or unprocessed budesonide. Furthermore, the spray-dried powders obtained from the 2-fluid nozzle spray drier, i.e., (i) and (ii), exhibited co-deposition of budesonide and theophylline at the same weight ratio in the aerodynamic assessment using the New Generation Impactor. In contrast, the depositions of budesonide and theophylline deviated from the starting weight ratio in the aerodynamic assessment of spray-dried powders obtained from the 3-fluid nozzle spray drier, i.e., (iii) and (iv). Based on these results, the powders spray-dried from the suspension by using the 2-fluid nozzle spray drier, i.e., (ii), offered the best formulation properties given the physically stable crystalline solid-state properties and the co-deposition profile.",
author = "Donglei Leng and Kissi, {Eric Ofosu} and Korbinian L{\"o}bmann and Kaushik Thanki and Elias Fattal and Thomas Rades and Camilla Foged and Mingshi Yang",
year = "2019",
month = mar,
day = "7",
doi = "10.1208/s12249-019-1344-9",
language = "English",
volume = "20",
journal = "A A P S PharmSciTech",
issn = "1530-9932",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy

AU - Leng, Donglei

AU - Kissi, Eric Ofosu

AU - Löbmann, Korbinian

AU - Thanki, Kaushik

AU - Fattal, Elias

AU - Rades, Thomas

AU - Foged, Camilla

AU - Yang, Mingshi

PY - 2019/3/7

Y1 - 2019/3/7

N2 - Corticosteroid resistance poses a major challenge to effective treatment of chronic obstructive pulmonary diseases. However, corticosteroid resistance can be overcome by co-administration of theophylline. The aim of this study was to formulate the corticosteroid budesonide with theophylline into inhalable dry powders intended for pulmonary combination therapy. Four types of spray-dried powders were prepared: (i) budesonide and theophylline co-dissolved and processed using a 2-fluid nozzle spray drier, (ii) budesonide nanocrystals and dissolved theophylline co-dispersed and processed using a 2-fluid nozzle spray drier, (iii) dissolved budesonide and dissolved theophylline processed using a 3-fluid nozzle spray drier, and (iv) budesonide nanocrystals and dissolved theophylline processed using a 3-fluid nozzle spray drier. Spray drying from the solutions resulted in co-amorphous (i) and partially amorphous powders (iii), whereas spray drying of the nanosuspensions resulted in crystalline products (ii and iv). Even though budesonide was amorphous in (i) and (iii), it failed to exhibit any dissolution advantage over the unprocessed budesonide. In contrast, the dissolution of budesonide from its nanocrystalline formulations, i.e., (ii) and (iv), was significantly higher compared to a physical mixture or unprocessed budesonide. Furthermore, the spray-dried powders obtained from the 2-fluid nozzle spray drier, i.e., (i) and (ii), exhibited co-deposition of budesonide and theophylline at the same weight ratio in the aerodynamic assessment using the New Generation Impactor. In contrast, the depositions of budesonide and theophylline deviated from the starting weight ratio in the aerodynamic assessment of spray-dried powders obtained from the 3-fluid nozzle spray drier, i.e., (iii) and (iv). Based on these results, the powders spray-dried from the suspension by using the 2-fluid nozzle spray drier, i.e., (ii), offered the best formulation properties given the physically stable crystalline solid-state properties and the co-deposition profile.

AB - Corticosteroid resistance poses a major challenge to effective treatment of chronic obstructive pulmonary diseases. However, corticosteroid resistance can be overcome by co-administration of theophylline. The aim of this study was to formulate the corticosteroid budesonide with theophylline into inhalable dry powders intended for pulmonary combination therapy. Four types of spray-dried powders were prepared: (i) budesonide and theophylline co-dissolved and processed using a 2-fluid nozzle spray drier, (ii) budesonide nanocrystals and dissolved theophylline co-dispersed and processed using a 2-fluid nozzle spray drier, (iii) dissolved budesonide and dissolved theophylline processed using a 3-fluid nozzle spray drier, and (iv) budesonide nanocrystals and dissolved theophylline processed using a 3-fluid nozzle spray drier. Spray drying from the solutions resulted in co-amorphous (i) and partially amorphous powders (iii), whereas spray drying of the nanosuspensions resulted in crystalline products (ii and iv). Even though budesonide was amorphous in (i) and (iii), it failed to exhibit any dissolution advantage over the unprocessed budesonide. In contrast, the dissolution of budesonide from its nanocrystalline formulations, i.e., (ii) and (iv), was significantly higher compared to a physical mixture or unprocessed budesonide. Furthermore, the spray-dried powders obtained from the 2-fluid nozzle spray drier, i.e., (i) and (ii), exhibited co-deposition of budesonide and theophylline at the same weight ratio in the aerodynamic assessment using the New Generation Impactor. In contrast, the depositions of budesonide and theophylline deviated from the starting weight ratio in the aerodynamic assessment of spray-dried powders obtained from the 3-fluid nozzle spray drier, i.e., (iii) and (iv). Based on these results, the powders spray-dried from the suspension by using the 2-fluid nozzle spray drier, i.e., (ii), offered the best formulation properties given the physically stable crystalline solid-state properties and the co-deposition profile.

U2 - 10.1208/s12249-019-1344-9

DO - 10.1208/s12249-019-1344-9

M3 - Journal article

C2 - 30847607

VL - 20

JO - A A P S PharmSciTech

JF - A A P S PharmSciTech

SN - 1530-9932

IS - 3

M1 - 137

ER -

ID: 214571155